TAGCyx Biotechnologies uses its proprietary Xenoligo technology platform to generate novel DNA aptamers containing an artificial nucleotide that have high affinity and selectivity for target proteins.

image: Gary Kleiger's lab on UNLV's campus has been a hub of activity in recent years, playing a significant role in a new realm of drug discovery -- one that could potentially provide a solution for ...

Middle-sized biological molecules (e.g., peptides, nucleic acids), namely ‘aptamers’, are utilized to inhibit disease-related target proteins. Aptamers are recognized as promising future drug ...

New assays based on iPSC help accelerate drug discovery by giving drug innovators in neurodegenerative diseases high quality data on a broad range of disease-relevant read-outs LEIDEN, Netherlands, ...

SOUTH SAN FRANCISCO, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, ...

Debiopharm, a Swiss-based global biopharmaceutical company, and Ubix Therapeutics, a South Korea-based biotech company, announced their co-research agreement combining two novel proprietary ...

Dublin, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The "Drug Discovery Informatics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The drug discovery informatics market ...

CHO cells are the predominant host for biotherapeutic protein expression with approximately 70% of licensed biologics manufactured in Chinese Hamster Ovary (CHO) cells. The ability to express ...